Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B.

Kenneth W Lin1, Jeffrey T Kirchner

  • 1Department of Family and Community Medicine, Lancaster General Hospital, Lancaster, Pennsylvania 17604, USA.

American Family Physician
|January 20, 2004
PubMed
Summary
This summary is machine-generated.

Hepatitis B affects over 400 million globally, causing significant deaths from liver cancer. Vaccination has reduced new infections, but chronic hepatitis B requires ongoing medical therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lumipulse Blood Biomarker Test for Diagnosis of Alzheimer Disease.

American family physician·2026
Same author

Historical Perspectives on Race-Based Medicine in American Family Physician.

American family physician·2025
Same author

Providing Reminders and Education Prior to lung cancer screening: Feasibility and acceptability of a multilevel approach to address disparities in lung cancer screening.

Translational behavioral medicine·2025
Same author

Evidence Considerations for Recent USPSTF Recommendations.

American family physician·2025
Same author

PSA Screening: Shared Decision-Making Is a Flawed Approach.

American family physician·2025
Same author

An Estimate of Preventable Harms Associated With Screening Colonoscopy Overuse in the U.S.

AJPM focus·2024
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis B virus (HBV) infection poses a substantial global health burden, leading to widespread morbidity and mortality.
  • Over 400 million individuals worldwide, including 1.25 million in the U.S., live with chronic hepatitis B.
  • Chronic HBV infection is a leading cause of cirrhosis and hepatocellular carcinoma (liver cancer) in the United States, accounting for approximately 5,000 deaths annually.

Purpose of the Study:

  • To summarize the epidemiology, transmission, prevention, and treatment of Hepatitis B.
  • To highlight the impact of vaccination programs on new Hepatitis B infections.
  • To outline current medical therapies for chronic Hepatitis B.

Main Methods:

  • Review of epidemiological data on Hepatitis B prevalence and mortality.

Related Experiment Videos

  • Analysis of transmission routes, including sexual contact, intravenous drug use, occupational, and perinatal exposure.
  • Summary of the efficacy of Hepatitis B vaccines and the impact of vaccination programs.
  • Overview of risk factors for progression to chronic infection.
  • Compilation of available medical therapies for chronic Hepatitis B.

    • Main Results:

    • Hepatitis B causes significant global morbidity and mortality, with over 400 million chronically infected individuals worldwide.
    • Vaccination programs, particularly since the 1990s, have led to a marked reduction in new Hepatitis B infections in the U.S.
    • Key risk factors for chronicity include age at infection and immune status, with 15-30% of acute cases progressing to chronic infection.
    • Established medical therapies for chronic Hepatitis B include interferon alfa-2b, lamivudine, and adefovir dipivoxil.

    Conclusions:

    • Hepatitis B remains a critical global health concern requiring continued prevention and management strategies.
    • While vaccination has been highly effective in reducing incidence, a significant population remains at risk for severe outcomes like liver cancer.
    • Effective medical treatments are available for chronic Hepatitis B, targeting viral suppression and disease progression.